LITHIUM CARBONATE


Trade Names	ESKALITH ESKALITH CR LITHANE LITHIUM CARBONATE LITHOBID LITHONATE LITHOTABS
Synonyms	CP-15,467-61 CP-15467-61 CP-1546761 Camcolit 250 Camcolit 400 Eskalith Eskalith cr Liskonum Lithane Lithium carbonate Lithobid Lithonate Lithotabs NSC-16895 Phasal
Status
Molecule Category	Salt-form
UNII	2BMD2GNA4V
EPA CompTox	DTXSID1023784
Parent Compound:	LITHIUM


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	XGZVUEUWXADBQD-UHFFFAOYSA-L
Smiles	O=C([O-])[O-].[Li+].[Li+]
InChI	InChI=1S/CH2O3.2Li/c2-1(3)4;;/h(H2,2,3,4);;/q;2*+1/p-2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	CLi2O3
Molecular Weight	73.89
AlogP	None
Hydrogen Bond Acceptor	None
Hydrogen Bond Donor	None
Number of Rotational Bond	None
Polar Surface Area	None
Molecular species	None
Aromatic Rings	None
Heavy Atoms	None

Pharmacology

Mechanism of Action	Action	Reference
Glycogen synthase kinase-3 inhibitor	INHIBITOR	PubMed Wikipedia FDA

	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)

Target Conservation


Protein: Glycogen synthase kinase-3 Description: Glycogen synthase kinase-3 alpha Organism : Homo sapiens P49840 ENSG00000105723












Protein: Glycogen synthase kinase-3 Description: Glycogen synthase kinase-3 beta Organism : Homo sapiens P49841 ENSG00000082701

Cross References

Resources	Reference
ChEBI	6504
ChEMBL	CHEMBL1200826
DrugBank	DB14509
FDA SRS	2BMD2GNA4V
KEGG	C07964
PubChem	11125
SureChEMBL	SCHEMBL25389

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).